Substance / Medication

Bosentan anhydrous

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

55 trials linked to this intervention

55
Total Trials
13
Recruiting
16
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Safety of Pulmonary Vasodilator and Inodilator Drugs in Congenital Heart Disease Surgery: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Ollosu Martina, Tripodi Vincenzo Francesco, Aresu Carlotta et al. · J Cardiothorac Vasc Anesth · 2026
PMID: 40968005Meta-Analysis
Prevalence and risk factors of portopulmonary hypertension in chronic liver disease: systematic review and meta-analysis.
Alsaleh Tareq, Harb Amir, Chapagain Parikshit et al. · Clin Res Hepatol Gastroenterol · 2026
PMID: 41412478Meta-Analysis
The volume-outcome relationship for pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.
Heuts Samuel, Kawczynski Michal J, Leus Arthur et al. · Eur Respir J · 2025
PMID: 39572220Meta-AnalysisFull text (PMC)
Pulmonary hypertension in preterm neonates with bronchopulmonary dysplasia: a meta-analysis.
Mascarenhas Dwayne, Al-Balushi Marwa, Al-Sabahi Aida et al. · Arch Dis Child Fetal Neonatal Ed · 2025
PMID: 39603794Meta-Analysis
Efficacy of iron replacement in pulmonary hypertension: A systematic review.
Baral Tejaswini, Malakapogu Pravachana, Shyma Zuha et al. · Nutr Health · 2025
PMID: 39711168Meta-AnalysisFull text (PMC)
Efficacy and Safety of Treating Pulmonary Arterial Hypertension With Imatinib: A Meta-Analysis of Randomized Controlled Trials.
Chen Xiaofa, Xue Bijuan, Xu Lina · J Cardiovasc Pharmacol · 2025
PMID: 39745285Meta-Analysis
Insights from 3D echocardiography: unveiling the prognostic value of RV function in pulmonary hypertension: a systematic review and meta-analysis.
Ahmad Ashfaq, Wang Xiaoyu, Li Lingling et al. · Int J Cardiovasc Imaging · 2025
PMID: 39806166Meta-Analysis
A Comprehensive Review of Artificial Intelligence (AI) Applications in Pulmonary Hypertension (PH).
Attaripour Esfahani Sogol, Baba Ali Nima, Farina Juan M et al. · Medicina (Kaunas) · 2025
PMID: 39859065Meta-AnalysisFull text (PMC)
A Cross-Species and Sex-Specific Meta-Analysis of Transcriptomic Studies of Pulmonary Hypertension.
Zhao Lan, Cunningham Christine M, Hong Jason et al. · Am J Respir Cell Mol Biol · 2025
PMID: 39928415Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bosentan anhydrous (substance)
SNOMED CT
1268952004
UMLS CUI
C2825457

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
55
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.